Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Platelets and Anticoagulant Capacity in Patients with Inflammatory Bowel Disease

Larsen T.B.a · Nielsen J.N.b · Fredholm L.b · Lund E.D.b · Brandslund I.b · Munkholm P.c · Hey H.d

Author affiliations

aDepartment of Clinical Biochemistry, Section for Thrombosis and Hemostasis, Aalborg Hospital, Aalborg, bDepartment of Clinical Biochemistry, Vejle County Central Hospital, Vejle, cDepartment of Medical Gastroenterology, University Hospital of Copenhagen, Copenhagen, and dDepartment of Medical Gastroenterology, Vejle County Central Hospital, Vejle, Denmark

Corresponding Author

Torben Bjerregaard Larsen, MD, PhD

Department of Clinical Biochemistry, Section for Thrombosis and Hemostasis

Aalborg Hospital, Hobrovej 18–22, PO Box 365

DK–9100 Aalborg (Denmark)

Tel. +45 9932 3180, Fax +45 9813 1196, E-Mail tblarsen@dadlnet.dk

Related Articles for ""

Pathophysiol Haemost Thromb 2002;32:92–96

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Patients with inflammatory bowel disease (IBD) are susceptible to thromboembolic complications. Several mechanisms can be responsible, including abnormal regulation of coagulation activity, disturbances of fibrinolysis, inflammatory reactions and thrombocytosis. The aim of this study was to assess hemostatic alterations in these parameters during exacerbation of disease. We studied disease activity in 99 IBD patients receiving anti-inflammatory therapy, in relation to: procoagulant markers, i.e. prothrombin fragment F1 + 2 (F1 + 2), D-dimer and platelet count, anticoagulant markers, i.e. protein C, protein S and antithrombin, and a mediator of inflammation (IL-6). Coagulation activity and platelet count were increased during active disease in IBD patients compared with those in a state of remission. The IL-6 concentrations were positively correlated with disease activity and thrombocytosis in patients with ulcerative colitis, but no association with the anticoagulant capacity could be demonstrated except for a decrease in protein C during high disease activity.

© 2002 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: July 12, 2002
Issue release date: July 2002

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 3

ISSN: 1424-8832 (Print)
eISSN: 1424-8840 (Online)

For additional information: http://www.karger.com/PHT

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.